

Concise asymmetric syntheses of (–)-lentiginosine and of its pyrrolizidinic analogue

Tahar Ayad, Yves Génisson,* Michel Baltas* and Liliane Gorrichon

LSPCMIB, UMR 5068, Université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse, France.

E-mail: baltas@chimie.ups-tlse.fr, genisson@chimie.ups-tlse.fr; Fax: +33 (0)5 61 55 82 45; Tel: +33 (0)5 61 55 62 99

Received (in Cambridge, UK) 11th December 2002, Accepted 20th January 2003

First published as an Advance Article on the web 29th January 2003

(–)-Lentiginosine and its pyrrolizidinic analogue have been prepared in a straightforward five-step sequence from a versatile chiral *cis*- α,β -epoxyamine.

We recently demonstrated that *cis*- α,β -epoxyamine **1**, readily prepared from the corresponding chiral epoxyaldehyde, is a valuable precursor of five-membered ring azasugars (Fig. 1).¹ We wish to describe here the extension of this methodology to the asymmetric synthesis of polyhydroxylated indolizidines and pyrrolizidines.




Fig. 1

In our previous work, the epoxyamine precursor **1** was efficiently transformed into a polyhydroxylated pyrrolizidine *via* the regiocontrolled C-3 opening of the epoxide, followed by the Appel cyclisation of the activated primary alcohol, and olefin dihydroxylation (Fig. 1). We envisioned that the vinyl moiety, instead of being directly oxidised, could be first engaged in a ring closing metathesis (RCM), allowing access to bicyclic analogues of five-membered ring azasugars (Fig. 2).² At some stage this would require the attachment onto the amine of a second olefinic partner, namely a butenyl residue for indolizidine syntheses and an allyl moiety for the preparation of pyrrolizidines.


Lentiginosine was targeted to validate our synthetic plan. Indeed this dihydroxylated indolizidine possesses some unique features, being the least hydroxylated biologically active bicyclic azasugar, and the most potent inhibitor of amyloglucosidase.³ It has therefore inspired a lot of synthetic work, mostly based on chiral pool starting material, relying much more rarely on asymmetric synthesis.⁴ We also wished to demonstrate the flexibility of our approach in preparing a novel pyrrolizidinic analogue of lentiginosine.

The amino triol **2**, possessing the relative configuration related to lentiginosine, was prepared in 70% yield by acidic hydrolysis of (2*S*, 3*R*, 4*R*)- α,β -epoxyamine **1** (Scheme 1). Ring opening, occurring exclusively at C-2, was accompanied by the desilylation of the primary alcohol. Direct introduction of the butenyl moiety *via* the alkylation of the unreactive secondary amine **2** then required considerable experimentation. It was however preferred to the alternative amine acylation which

implicates an additional carbonyl reduction step.⁵ Although most of the conditions tested proved unsuccessful, treatment of **2** with butenyl triflate gratifyingly afforded the desired tertiary amine **3** in 67% yield. Use of proton-sponge® as base proved to be determining for completion of the reaction. The allylation of the secondary amine **2** was achieved in 85% yield under standard conditions to afford **4**.

With the dienic precursors **3** and **4** in hand, we were in a position to test the key RCM step. Preliminary studies were conducted on the partially protected (1,2)-acetone derivative of **3** (not shown). They indicated that the second generation 1,3-bis(mesityl)-2-imidazolidinylidene-substituted ruthenium Grubbs catalyst (Grubbs II) was superior to the classical benzylidene-bis(tricyclohexylphosphine)dichlororuthenium (Grubbs I) in forming the tetrahydropyridine ring. To our satisfaction, treatment of the fully unprotected precursor **3** with the Grubbs II ruthenium complex in toluene at 70 °C for less than an hour led to the desired cyclised compound **5** in 66% yield (Scheme 1). Formation of the dihydropyridine ring from the *N*-allylated free triol **4** was best accomplished with the Grubbs I catalyst, giving **6** in 70% yield. Both derivatives **5** and **6** possess an intracyclic olefin well positioned for further oxidative functionalisation. They therefore represent valuable intermediates for the synthesis of various polyhydroxylated bicyclic alkaloids.

Completion of the synthesis required formation of the dihydroxylated five-membered ring of the lentiginosine framework. Catalytic hydrogenation first ensured *N*-debenzylation with concomitant olefin saturation, yielding piperidine **7** and pyrrolidine **8** (Scheme 2). Appel cyclisation of **7** then delivered, in 67% yield, the all-*R*-lentiginosine (**9**). This compound ($[\alpha]_{25}^{D} -2.0^{\circ}$ (*c* 1.0, MeOH); lit.^{3b,4b,4f,4j} $-1.6, -2.6, -3.05, -4.5$) had spectral data in agreement with that reported in the literature.⁴ Dihydroxypyrrolizidine **10** was prepared from **8** in the same manner and in comparable yield.[†] The starting epoxyamine **1** being equally available in both optical series, this



Scheme 1 Reagents and conditions: i, 3 M H₂SO₄ (8 eq.), dioxane, reflux, 70%; ii, for *n* = 0: allylbromide (4 eq.), NaHCO₃ (6 eq.), THF/H₂O, rt, 85%; for *n* = 1: 4-butenyltrifluoromethanesulfonate (1.2 eq.), proton-sponge® (1.5 eq.), CH₂Cl₂, rt, 67%; iii, for *n* = 0: Grubbs I cat. (8 mol%), CH₂Cl₂, reflux, 70%; for *n* = 1: Grubbs II cat. (8 mol%), toluene, 70 °C, 66%. Grubbs I cat.: benzylidene-bis(tricyclohexylphosphine)dichlororuthenium; Grubbs II cat.: benzylidene[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(tricyclohexylphosphine)ruthenium.





Fig. 2



Scheme 2 Reagents and conditions: i, 12 bar H₂, 10% Pd/C (10% w/w), MeOH, 12 M HCl (cat.), for n = 0, 1: 90%; ii, PPh₃ (2 eq.), CCl₄ (2 eq.), Et₃N (2 eq.), DMF, rt, for n = 0, 1: 68%.




Fig. 3 Effect of substrate (*p*-nitrophenyl- α -D-glucopyranoside) concentration on amyloglucosidase (*Aspergillus niger*) inhibition by various concentrations of **10**.

new route also offers a direct access to the other enantiomer of these bicyclic azasugars.

This synthetic work was complemented by enzymatic inhibition experiments with respect to the amyloglucosidase from *Aspergillus niger*.[‡] An IC₅₀ of 25.5 $\mu\text{g mL}^{-1}$ was measured for our sample of (–)-lentiginosine. This value is in agreement with the IC₅₀ (17 $\mu\text{g mL}^{-1}$) that Brandi *et al* found for the laevorotatory isomer, proposed to be the unnatural enantiomer of lentiginosine.^{3b} The novel dihydroxylated pyrrolizidine **10** was found to display an IC₅₀ of 27.3 $\mu\text{g mL}^{-1}$, comparable with that of (–)-lentiginosine, and to behave as a

competitive inhibitor ($K_i = 121 \mu\text{M}$), as indicated by the Lineweaver–Burk plot shown in Fig. 3.

The enzyme was kindly provided by Pr. P. Monsan, INSA, Toulouse, France. We are grateful to S. Gavaldà, R. Braga and Dr C. Blonski for their help in enzymatic inhibition experiments. T. A. acknowledges the ‘Ministère de l’Éducation Nationale de la Recherche et des Technologies’ for a grant.

Notes and references

[†] Characteristic data for compound **10**: [α]_D²⁵ +7.6° (c 1.3, MeOH); δ_{H} (400 MHz, CD₃OD): 4.23–4.13 (1H, m, H-2), 3.90 (1H, br s, H-1), 3.63–3.55 (1H, m, H-7a), 3.19 (2H, AB of ABX, $J_{\text{ab}} = 11.6 \text{ Hz}$, $J_{\text{ax}} = 5.2 \text{ Hz}$, $J_{\text{bx}} = 4.4 \text{ Hz}$ ($\delta_{\text{a}} - \delta_{\text{b}} = 230 \text{ Hz}$), H-3 and H-3'), 3.28–3.25 (1H, m, H-5), 3.23–2.90 (1H, m, H-5'), 2.26–2.10 (1H, m, H-7), 2.09–1.93 (2H, m, H-7' and H-6), 1.83–1.78 (1H, m, H-6'); δ_{C} (100 MHz, CD₃OD): 82.8 (C-1), 80.0 (C-2), 75.0 (C-7a), 61.0 (C-3), 58.9 (C-5), 32.1 (C-7), 28.0 (C-6); mass spectrum (DCI): m/z 144 (MH⁺, 100); HRMS: m/z (M⁺) calc. for C₇H₁₃NO₂ 143.0946, found 143.0951.

[‡] Conditions were essentially identical to those used in ref. 3b.

- 1 T. Ayad, Y. Génisson, M. Baltas and L. Gorrichon, *Synlett*, 2001, 866.
- 2 For a review of the use of RCM in synthesis of bicyclic azasugars, see: U. K. Pandit, H. S. Overkleeft, B. C. Borer and H. Bieräugel, *Eur. J. Org. Chem.*, 1999, 959; for selected recent examples, see: T. Subramanian, C.-C. Lin and C.-C. Lin, *Tetrahedron Lett.*, 2001, **42**, 4079; C. F. Klitzke and R. A. Pilli, *Tetrahedron Lett.*, 2001, **42**, 5605; K. B. Lindsay and S. G. Pyne, *J. Org. Chem.*, 2002, **67**, 7774.
- 3 (a) Isolation: I. Pastuszak, R. J. Molyneux, L. F. James and A. D. Elbein, *Biochemistry*, 1990, **29**, 1886; (b) activity: A. Brandi, S. Cicchi, F. M. Cordero, R. Frignoli, A. Goti, S. Picasso and P. Vogel, *J. Org. Chem.*, 1995, **60**, 6806.
- 4 (a) For chiral pool syntheses, see: H. Yoda, H. Kitayama, T. Katagiri and K. Takabe, *Tetrahedron: Asymmetry*, 1993, **4**, 1455; (b) M. K. Gurjar, L. Ghosh, M. Syamala and V. Jayasree, *Tetrahedron Lett.*, 1994, **35**, 8871; (c) R. Giovannini, E. Marcantoni and M. Petrini, *J. Org. Chem.*, 1995, **60**, 5706; (d) A. Goti, F. Cardona and A. Brandi, *Synlett*, 1996, 761; (e) H. Yoda, M. Kawauchi and K. Takabe, *Synlett*, 1998, 137; (f) A. E. McCaig, K. P. Meldrum and R. H. Wightman, *Tetrahedron*, 1998, **54**, 9429; (g) D.-C. Ha, C.-S. Yun and Y. Lee, *J. Org. Chem.*, 2000, **65**, 621; (h) H. Yoda, H. Katoh, Y. Ujihara and K. Takabe, *Tetrahedron Lett.*, 2001, **42**, 2509; (i) J. Rabczko, Z. Urbanczyk-Lipkowska and M. Chmielewski, *Tetrahedron*, 2002, **58**, 1433; (j) K. L. Chandra, M. Chandrasekhar and V. K. Singh, *J. Org. Chem.*, 2002, **67**, 4630; for asymmetric syntheses, see (k) S. Nukui, M. Sodeoka, H. Sasai and M. Shibasaki, *J. Org. Chem.*, 1995, **60**, 398; (l) M. O. Rasmussen, P. Delair and A. E. Greene, *J. Org. Chem.*, 2001, **66**, 5438; (m) S. H. Lim, S. Ma and P. Beak, *J. Org. Chem.*, 2001, **66**, 9056; (n) Z.-X. Feng and W.-S. Zhou, *Tetrahedron Lett.*, 2003, **44**, 497.
- 5 This stepwise formation of tetrahydropyridine ring has been used in several syntheses of polyhydroxylated indolizidines. For lentiginosine, see: refs. 4j and 4m. For related alkaloids, see: C. Paolucci and L. Mattioli, *J. Org. Chem.*, 2001, **66**, 4787.